Fig. 5
From: The timeline of epigenetic drug discovery: from reality to dreams
Examples of KMT inhibitors including the clinical candidates sinefungin (compound 30), pinometostat (compound 31), GSK2816126 (compound 32), tazemetostat (compound 33), compound GSK3326595 (compound 34), JNJ-64619178 (compound 35), and GSK3368715 (compound 36)